Newsfeeds Archive - Page 5 of 7

1 minute read

Stifel Downgrades Fate Therapeutics to Hold, Lowers Price Target to $5.3

January 6, 8:54 AM

Stifel analyst Benjamin Burnett downgrades Fate Therapeutics (NASDAQ:FATE) from Buy to Hold and lowers the price target from $107 to $5.3.

FATE

1 minute read

EF Hutton Maintains Buy on Fate Therapeutics, Lowers Price Target to $10

By Benzinga Newsdesk

January 6, 8:28 AM

EF Hutton analyst Tony Butler maintains Fate Therapeutics (NASDAQ:FATE) with a Buy and lowers the price target from $16 to $10.

FATE

1 minute read

Cowen & Co. Downgrades Fate Therapeutics to Market Perform

By Benzinga Newsdesk

January 6, 7:06 AM

Cowen & Co. analyst Tyler Van Buren downgrades Fate Therapeutics (NASDAQ:FATE) from Outperform to Market Perform.

FATE

1 minute read

BMO Capital Downgrades Fate Therapeutics to Market Perform, Lowers Price Target to $7

By Benzinga Newsdesk

January 6, 6:02 AM

BMO Capital analyst Etzer Darout downgrades Fate Therapeutics (NASDAQ:FATE) from Outperform to Market Perform and lowers the price target from $20 to $7.

FATE

1 minute read

EF Hutton Initiates Coverage On Fate Therapeutics with Buy Rating, Announces Price Target of $16

By Benzinga Newsdesk

January 5, 5:34 AM

EF Hutton analyst Tony Butler initiates coverage on Fate Therapeutics (NASDAQ:FATE) with a Buy rating and announces Price Target of $16.

FATE

1 minute read

Cathie Wood Can’t Keep Hands Off Tesla As Holiday Season Binge Grows To Nearly Half A Million Shares

By Bhavik Nair

January 4, 9:44 PM

Cathie Wood-led ARK Investment Management bought 21,050 shares of Tesla Inc (NASDAQ: TSLA) on Wednesday at an estimated valuation of over $2.39 million.

ARKK